Company intelligence / Profile preview
MagicRNA Biotechnology
Shenzhen, Guangdong, China
- Ownership
- Private
- Employees
- ~50
- Development stage
- Preclinical
01
Overview
MagicRNA Biotechnology specializes in the development and delivery of nucleic acid drugs, particularly focusing on mRNA and oligonucleotide therapeutics. The company’s lead pipeline asset targets cancer and remains at the preclinical stage. They have developed proprietary technologies for efficient nucleic acid drug delivery, including novel amino lipids. No clinical results have been published as of May 2025.
- Therapeutic areas
- OncologyOther
- Modalities
- mRNA drugsOligonucleotidesCyclic RNANucleic acid drug delivery systems
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on MagicRNA Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MagicRNA Biotechnology.